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ABSTRACT
Introduction: The androgen receptor (AR) plays an important role in normal development 
of the prostate gland, as well as in prostatic neoplasms. Transcriptional regulation by 
AR is modulated by its interaction with co-activators or co-repressors, such as NCoR1 
(nuclear receptor co-repressor 1), which is involved in reducing AR activity over the 
target gene transcription. 
Methods: To identify the role of NCoR1 in the prostate cancer androgen independence 
in a cell line model, we aimed to evaluate the effects of silencing NCoR1 on 
prostate-specific antigen (PSA) gene expression, the proliferative response and 
PSA secretion on the supernatant of C4-2B and LNCaP cells that were submitted 
to small interfering RNAs (siRNAs) transfection, and to treatments with different 
androgen dosages. 
Results: In LNCaP and C4-2B cells with no dihydrotestosterone (DHT) treatment, a 
decrease in PSA mRNA expression was observed 48 hours and 72 hours after gene 
silencing in the siNCoR group when compared to the control and siNC groups. The 
LNCaP and C4-2B cells showed a biphasic pattern in response to dihydrotestosterone 
treatment in transfected groups (siNCoR and siNC) as well as in the control condition 
(without transfection). The secretion of PSA in cell supernatant of LNCaP and C4-2B 
cells was higher in the siNCoR group, and, in relation to hormonal treatment, higher 
in the 10-8 M DHT group. 
Conclusions: A reduction in the NCoR1 levels seems to have a double influence on 
the activity of AR in PCa cells. These results suggest that NCoR may act as an AR 
co-repressor depending upon hormonal stimulation. 
Keywords: Prostatic neoplasms; castration-resistant; prostatic neoplasm; NCoR1; 
gene silencing
Diseases that affect the prostate, such as chronic inflammatory lesions 
(prostatitis), benign prostatic hyperplasia (BPH), and prostate cancer (PCa) are 
related to the aging male1. Currently, PCa has the second highest worldwide 
incidence of cancer and is considered the sixth leading cause of death among 
men2. The higher incidence of prostate cancer has increasingly motivated 
studies to investigate the mechanisms involved in the pathophysiology of 
this disease3.
Androgens play a critical role in the normal development of the prostate 
gland1 and are also involved in the tumorogenesis of this organ4-6. Androgen 
receptor (AR) mediates the biological effects of androgens on cells7,8, 
promoting epithelial luminal cell differentiation and regulating the transcription 
of the genes encoding proteins involved in the normal physiology of the 
prostate gland, like PSA3. Inhibition of the transcriptional activity of AR by 
androgen deprivation is still the primary choice treatment9. Initially, this 
approach is effective, but in about 70-80% of men, at a later stage the PCa 
cells acquire proliferative ability independent of androgen10. The efficacy 
of different therapeutic approaches to androgen suppression is directly 
related to the ability to consistently reduce serum total testosterone, but 
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when progression occurs despite the maintenance 
of low serum levels of androgens, the cancer is 
then characterized as “androgen-independent” or 
“hormone-refractory”11.
Although the main components of the transcriptional 
pathway mediated by AR and the effect of androgens 
on it are described in detail, little is known about 
the role of co-activators and co-repressors during 
progression to androgen independence in the refractory 
PCa to hormonal deprivation12. Co-activators and 
co-repressors regulate the transcriptional activity 
of AR by modulating the interactions between the 
receptor and the transcription initiation complex13; 
the co-activators are usually recruited to enhance 
gene expression while co-repressors bind to nuclear 
receptors mainly repressing transcription14. This 
increases the regulation by co-activators, as the 
low co-repressor expression has been shown 
to contribute to tumor progression15. The NCoR 
(nuclear receptor co-repressor) interacts with histone 
deacetylases to repress transcription16, so the NCoR 
interacts with AR and represses the transcriptional 
activity stimulated by dihydrotestosterone (DHT), 
indicating that this protein is a physiological regulator 
of AR activity17. The uncoupling of co-repressors 
and AR co-activator recruitment occur after the 
conformational changes promoted by the binding 
of androgens to the ligand binding site (LDB), so 
that the regulation exerted by these cofactors is 
dependent on the presence or absence of androgens 
in the prostatic cell18,19.
Studies involving silencing of the AR signaling 
pathway using RNAi can contribute to the understanding 
of the growth mechanisms of the tumor refractory to 
hormone deprivation therapy and to the development 
of new therapeutic approaches.
METHODS
Cell Lines and Culture
The prostatic cancer cell lines LNCaP (ATCC®, 
CRL-1740™, passages number #34 to #38) and 
C4-2B (MD Anderson Cancer Center, passages 
number #17 to #20) were cultured in RPMI 1640 
(GIBCO, BRL) supplemented with 10% (v/v) fetal 
bovine serum (FBS) (GIBCO, BRL) and 1% (v/v) 
kanamycin (Invitrogen, EUA). All cell lines were grown 
in a 37°C, humidified incubator in the presence of 5% 
(v/v) CO2 gas. Passages were made with Trypsin/
EDTA 0.25% (GIBCO, BRL).
Transfection with siRNA
After LNCaP and C4-2B cells reached about 
30 to 50% confluence, the culture medium was 
replaced by medium without antibiotics for 4 hours 
and then transfected using the Lipofectamine® 
2000 reagent (Invitrogen, EUA). We previously 
tested three sequences of small interfering RNAs 
(siRNAs) (10nM) (HSS114352, HSS114353, 
HSS114354), separately and in combination, 
in order to choose the best conditions for gene 
silencing. The smallest NCoR1 mRNA expression 
was achieved with the combination of HSS114352 
and HSS114353 sequences. The negative control 
group (siNC) received a scrambled sequence 
of siRNAs in the same concentration of NCoR1 
siRNA (Stealth RNAi siRNA Negative Control Low 
GC and High GC, Invitrogen, EUA). To control 
the transfection efficiency, we used BLOCK-iT™ 
Fluorescent Oligo (Invitrogen, EUA), following the 
manufacturer’s protocol.
PSA gene expression
The gene expression of PSA was assessed 
using Reverse Transcription Polymerase Chain 
Reaction (RT-PCR). LNCaP and C4-2B cells were 
seeded in 6-well plates (1 × 104 cells/well), divided 
into three groups for analysis (Control, siNCoR and 
siNC). After 48 hours or 72 hours of transfection, 
cells were lyzed with Tryzol® (Invitrogen, EUA) 
and the total RNA was extracted following the 
manufacturer’s protocol. The RNA amount was 
quantified using the Qubit fluorimeter (Qubit® 
RNA Assay Kit, Invitrogen, EUA). Complementary 
DNA (cDNA) synthesis was performed using the 
Super Script® III First-Strand Synthesis System 
for RT-PCR (Invitrogen, EUA) from 1 µg of RNA 
using the Oligo dT12-18 primer.
The evaluation of PSA gene expression was 
performed by RT-PCR of the PSA mRNA amplification 
with specific oligonucleotides20. The reaction was 
performed using Platinum SYBR® Green qPCR 
SuperMix-UDG (Invitrogen, EUA) and in the 7500 Fast 
equipment (Applied Biosystems). The amplification 
reaction was normalized by the reference gene 
SdhA (succinate dehydrogenase complex, subunit 
A, flavoprotein (Fp)).
Cell proliferation
LNCaP and C4-2B cells were seeded in 24-well 
plates (5 × 103 cells/well), divided into three groups for 
analysis (Control, siNCoR and siNC) and separated 
according to different doses of dihydrotestosterone 
(10-8M DHT and 10-13M DHT). After 48 hours of 
treatment, cells were transfected according to the 
analysis group. In the next 96 hours, the assessment 
of cell proliferation was performed using modified 
Sulforhodamine B assay (SR-B)21. For the SR-B assay, 
the culture medium was replaced by a culture medium 
without fetal bovine serum22 and the cells were fixed 
with 50% Trichloroacetic acid (TCA) (100 µL per well). 
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the Generalized Estimating Equations (GEE). The 
post-hoc Bonferroni test was performed to identify 
which groups differed. All analyses were performed 
using SPSS 18.0. Statistical significance was 
established at p < 0.05.
RESULTS
PSA mRNA expression
In LNCaP cells, we observed a decrease of PSA 
mRNA expression after 48 hours in the siNCoR group 
when compared to siNC (p < 0.05). All other groups 
showed no statistical difference in PSA expression, 
both at 48 and 72 hours after transfection (N = 4) 
(Figure 1A).
In C4-2B cells, after 48 hours of transfection, the 
PSA mRNA expression was lower in the siNCoR 
group compared to control and siNC groups (p < 0.05, 
N = 4). After 72 hours, PSA mRNA expression was 
lower in the siNCoR group compared to the control 
group (p < 0.05, N = 4) (Figure 1B).
The optical density (OD) was read at 510nm on a 
spectrophotometer (AnthosZenyth 200 rt).
To obtain the proportion of cell growth of each 
experimental subgroup, the final absorbance values 
were adjusted relative to the initial number of cells 
plated23. The control group was the subgroup without 
hormonal treatment, and which was not silenced, 
whose proliferation was considered to be 100%.
PSA secretion
LNCaP and C4-2B cells were seeded in 24-well 
plates (5 × 103 cells/well). The secreted PSA dosage 
was measured in the cell supernatant at two different 
times: just before the transfection and 72 hours after 
the transfection. The dosage was assessed using the 
kit Cobas® Total PSA (tPSA) (Roche Diagnostics, 
EUA). The results are expressed as delta PSA 
(PSA after transfection – PSA before transfection)/
proliferation rate.
Statistical analysis
Data from cell proliferation, PSA gene expression, 
and PSA secretion, were evaluated quantitatively by 
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Figure 1: A: PSA mRNA expression in LNCaP; B: C4-2B cells (48 and 72 hours) after siRNA transfection. In the comparison 
between gene silencing groups (Control, siNCoR, siNC): “a” differs significantly from Control and “b” differs significantly 
from siNCoR. The bars represent the mean ± standard deviation. p < 0.05; n = 4.
Cell Proliferation
A biphasic pattern of response to DHT 
concentrations was observed in all groups (control, 
siNCoR, and siNC) in both cell lines. In the LNCaP 
cell line, cells treated with 10-13 M DHT showed the 
highest levels of proliferation, followed by cells that 
were treated with 10-8 M DHT compared to cells 
without DHT (Control 5%). When comparing the 
silencing groups, the siNC group showed a higher 
proliferation rate than siNCoR with the same DHT 
treatment (Figure 2A).
In the C4-2B cell line, treatment with 10-13M 
DHT promoted higher levels of cell proliferation; 
however, cells treated with 10-8 M DHT showed 
less proliferation than the control group. The cells 
of the control group had proliferated more than 
siNCoR and siNC with the same DHT treatment 
(Figure 2B).
Costa et al.
http://seer.ufrgs.br/hcpaClin Biomed Res 2020;40(1)40
300
# #
£
a
a
#
a
#
£
a
b
#
#
£
a a a#
£
a
a
b
#
a
b
#
£
a
b
#
£ab
200
100
0
150
100
50
0
A
LN
C
aP
Pr
ol
ife
ra
tio
n 
ra
te
 (%
)
C
4-
2B
Pr
ol
ife
ra
tio
n 
ra
te
 (%
)
B
Control siNCoR siNC Control siNCoR siNC
Control 5% DHT 10-13M DHT 10-8M Control 5% DHT 10-13M DHT 10-8M
Figure 2: A: Proliferation rates of LNCaP; B: C4-2B cells submitted to NCoR1 silencing and DHT treatments. In the 
comparison between gene silencing groups (Control, siNCoR, siNC): “a” differs significantly from Control and “b” differs 
significantly from siNCoR. In the comparison between hormonal treatments (Control 5%, DHT 10-13M, DHT 10-8M): “#” 
differs significantly from Control 5% and “£” differs significantly from DHT 10-13M. The bars represent the mean ± standard 
deviation p < 0.05; n = 4.
PSA secretion
As observed in proliferation rates in response to 
hormonal treatment, PSA levels in the supernatant 
showed a biphasic pattern of response to DHT 
concentrations in all groups (control, siNCoR, and 
siNC). In both cell lines, cells treated with 10-8 M 
DHT presented the highest levels of PSA compared 
to cells treated with 10-13 M DHT and cells with no 
DHT treatment (Control 5%) (Figure 3A and 3B). 
Cells treated with 10-13 M DHT presented higher 
levels of PSA than cells without DHT treatment 
(Control 5%).
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Figure 3: A: PSA secretion levels in LNCaP; B: C4-2B cells submitted to NCoR1 silencing and DHT treatments. In the comparison 
between gene silencing groups (Control, siNCoR, siNC): “a” differs significantly from Control and “b” differs significantly from 
siNCoR. In the comparison between hormonal treatments (Control 5%, DHT 10-13M, DHT 10-8M): “#” differs significantly from 
Control 5% and “£” differs significantly from DHT 10-13M. The bars represent the mean ± standard deviation. p < 0.05; n = 4.
Comparing the silencing groups, we observed 
higher levels of PSA in the supernatant in the siNCoR 
group compared to control and siNC groups in almost 
all hormonal treatment subgroups.
DISCUSSION
The nuclear receptor co-repressor 1 is described as a 
transcription factor that represses transcriptional activity 
of the androgen receptor. When silencing NCoR1, it is 
assumed that the transcriptional repression mediated 
by the interaction of this co-repressor with AR would be 
reduced, which would result in greater activation of the 
AR signaling pathway. Then, the transcription of AR-
regulated genes, such as PSA, would increase, and 
the proliferation process could also be up-regulated 
in prostate cells in response to hormonal treatment. 
However, in our study, the reduced levels of NCoR1 in 
prostate cancer cells seemed to have no influence on 
NCoR1 silencing and prostate cancer cells function
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the increased transcriptional androgen receptor activity 
in prostate cancer cells. When we evaluated the PSA 
mRNA expression at 48 hours of siRNA transfection, 
we observed lower levels of this transcript in both cell 
lines (LNCaP and C4-2B cells). Since there was no 
difference in gene expression between the control and 
SINC groups in this experimental condition, we suggest 
that this reduction in PSA gene expression took place 
due to the decrease in NCoR1 levels in these cells. 
Hodgson and colleagues identified an increase in 
PSA expression after the depletion of NCoR19. The 
unexpected pattern observed in our study was also 
observed by Laschak and colleagues19, who evaluated 
the response of PC-3 cells (AR-negative prostate 
cancer cell line) and COS-1 cells (strain renal cell 
of monkey) to overexpression of the co-repressors 
NCoR and SMRT, co-transfected with AR and the PSA 
gene promoter. In COS-1 cells, the increased NCoR 
levels reduced the transcriptional activity of AR by 
50%, as expected. PC-3 cells, however, had shown 
an increase in PSA expression. To test whether these 
results were specific to this cell line, since it has no 
endogenous AR, the LNCaP cell line was transfected 
with the luciferase reporter gene using the promoter 
of the probasin gene, which is androgen-responsive, 
to determine the transcriptional activity of AR in the 
presence of increasing amounts of NCoR co-repressor. 
LNCaP cells overexpressing NCoR increased the 
transcriptional activity of endogenous AR by up to 
2.7 times, depending on the amount transfected. Two 
other strains of prostate cancer cells were evaluated: 
DU-PCa and PCa-V (AR-positive), and the same 
pattern was found. Thus, increased levels of NCoR and 
SMRT were not able to suppress the transactivation 
of AR in LNCaP, DU-CaP, and V-CAP cells, nor in 
PC-3 cells. Instead, they promoted an increase in the 
transcriptional activity of AR in CaP cells, suggesting a 
failure of NCoR to act as an AR, or even a new role for 
this protein in prostate cancer cells19. Our data agreed 
with the results from Laschak et al., since the NCoR did 
not respond as expected following overexpression of 
this co-repressor in prostate cancer cells19, nor when 
their levels were decreased in tumor cells, according 
to the data found in our study. 
Proliferation rates in response to NCoR silencing 
combined with treatment with DHT were also evaluated. 
Generally, the siNCoR group presented lower proliferations 
rates compared to the control and siNC groups, in 
both cell lines. This pattern is also as unexpected as 
the transcriptional activity of AR, since we expected 
that activation of the AR signaling pathway could 
increase the proliferation of PCa cells. Since NCoR1 
also acts to regulate the activity of nuclear receptors 
other than AR, it is possible that diminished levels can 
interfere with the activity of other nuclear receptors, 
thus changing the expression of other genes related 
to the rate of cell division. 
Regarding the influence of dihydrotestosterone 
on proliferation rates, cells treated with 10-13 M DHT 
showed higher proliferation rates than cells without 
treatment and cells treated with 10-8 M DHT. In LNCaP 
cells, which have a functional AR and are dependent 
on androgens, a biphasic pattern of response to DHT 
was observed: the group with the lower proliferation 
rate was the control group (without DHT), followed by 
the 10-8 M DHT and 10-13 M DHT groups, with the latter 
having the highest proliferation. These data corroborate 
previous studies, where the proliferation conditioned by 
androgens in response to different physiological doses 
is known to be biphasic: androgens in smaller doses at 
nanomolar levels (10-9 M) stimulate cell proliferation, while 
larger nanomolar level doses exert an anti-proliferative 
effect1,24. In C4-2B cells, we also observed responses 
to 10-13 M DHT and to 10-8 M DHT, but the higher dose 
presented lower proliferation rates than the control 
group. This difference between these two cell types 
could be due to the response to androgens. Whereas 
LNCaP is dependent on the stimulus of androgens to 
proliferate25, C4-2B cells are androgen-sensitive cells, 
i.e., cells that can respond to androgen stimulation but 
do not depend on this stimulus for their maintenance26,27. 
Thus, the absence of DHT in the control group does 
not exert the same anti-proliferative effect in C4-2B 
cells as observed in LNCaP cells.
PSA secretion in supernatant of C4-2B and LNCaP 
presented a similar pattern, with the siNCoR and siNC 
groups presenting higher levels of this protein compared 
to the control group. Furthermore, the higher dose of 
DHT stimulated the highest secretion of this protein. 
Comparing the gene expression and secretion profiles, 
the results are opposite: cells submitted to the silencing 
of NCoR presented lower levels of PSA mRNA, but 
higher levels of PSA secretion. However, to evaluate 
the PSA mRNA expression, the cells were not submitted 
to hormonal treatment, and had received only the 
testosterone stimulation of fetal bovine serum, which 
may vary within nanomolar levels (10-9 M)28.
Lee and colleagues described that LNCaP cells 
accounted for variability of different DHT concentrations 
to which they are exposed. Low DHT concentrations 
(10-12 to 10-10 M) stimulated cell proliferation, but cells 
presented low levels of PSA secretion. In contrast, when 
exposed to high concentrations of DHT (10-7 M), cells 
reduced their proliferative capacity, accompanied by 
an increase in the production and secretion of PSA29. 
The response of LNCaP cells to high concentrations 
of DHT is considered a result of a particular cellular 
event, since high levels of DHT can act by delaying 
AR degradation, which could culminate in the higher 
production of PSA and, in parallel, a decrease in cell 
proliferation29. Moreover, the treatment of LNCaP cells 
with androgens caused a decrease in the AR mRNA 
levels and a paradoxical increase in total AR quantity30,31. 
In addition, regarding the PCa cells dependence of 
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androgens, there are differences in the co-repressors 
expression, as noticed by Villagran et al. (2015), which 
observed an increase of NCoR1 expression in LNCaP 
cells in absence of androgens, whereas there was a 
decrease in the C4-2B cells32. The preformed multi-
subunit complexes may lack co-repressor(s) in the 
androgen-resistant PCa cells, which could provide for AR 
functions as a transcription factor in the low circulating 
androgen levels32. Thus, the response of the distinct 
cell lines may be due differential set of co-activators/
co-repressors and their interactions to the transcription 
machinery in the PCa cells.
In our study, the evaluation of gene expression 
and PSA secretion was performed under different 
hormonal stimulation. In the presence of unknown 
levels of testosterone (from FBS), a hormone with a 
lower affinity for AR than DHT, the transcription of the 
PSA gene was decreased in the group silenced for 
NCoR and may suggest the failure of NCoR to act as a 
co-repressor, since its silencing had no positive impact 
on the transcription of the PSA gene. In the presence 
of DHT stimulation, and higher binding affinity to AR, 
lower levels of NCoR led to the increased secretion 
of this protein in the supernatant of cells in culture. 
The well-characterized genomic pathway of androgen 
action regulates PSA gene transcription. Besides this 
pathway, it is known that androgens can act by non-
genomic signaling pathways that are characterized by 
rapid response, indicating the absence of transcription 
and the translation of genes that are responsive to 
androgens. In addition, it is possible that non-genomic 
activity of AR might influence its genomic activity and 
that of other nuclear receptors18. Thus, it is possible 
that the high levels of DHT (10-8 M) could be stimulating 
non-genomic pathways for AR signaling, which interact 
with genomic pathways and culminate in the increased 
translation of PSA mRNA or even trigger a signaling 
stabilization of PSA mRNA by increasing the levels of 
this secreted protein.
The study of the role of co-regulators in prostate 
cancer cell lines, as well as in primary cultures, may 
help to understand the pathophysiology of prostate 
cancer and the influence of these AR modulators on 
the development and maintenance of this malignancy, 
especially in cancers refractory to androgen deprivation 
therapy. Although NCoR has been extensively studied, 
most of these studies investigated the influence of 
this co-repressor on AR transcriptional activity in 
non-prostate cell lines17,19,33. The results of this study 
show slight differences from classic data presented 
in the literature, and further studies are needed to 
complement the information on the role of NCoR in 
androgen-independent tumors.
Our in vitro results showed that silencing the NCoR1 
co-repressor in prostate cancer cells may result in 
increased AR activity, since there were higher rates 
of PSA secretion when under the stimulus of high 
doses of dihydrotestosterone (10-8 M). However, the 
increased transcriptional activity of AR is not displayed 
in terms of an increase of PSA mRNA expression under 
the stimulation conditions of testosterone present in 
only FBS with which the medium is supplemented. 
Decreased levels of NCoR, contrary to expectations, 
do not appear to provide a proliferative advantage to 
C4-2B cells LNCaP, although all groups presented 
the expected increase in proliferation response to the 
stimulus of low doses of DHT (10-13 M).
Regardless of the mechanism involved, AR signaling 
plays a critical role in the development and progression 
of prostate cancer. Increased AR activity is fundamental 
in the processes that lead to androgen independence in 
prostate cancers refractory to androgen ablation therapy, 
which is the biggest obstacle to the successful treatment 
and control of PCa. Understanding the mechanisms 
that lead to the activation of the AR signaling pathway 
is extremely important for the development of effective 
therapies for hormone-refractory cancers. Further studies 
are needed to elucidate the molecular mechanisms by 
which AR co-repressors can respond in such different 
ways, leading to the activation of specific genes involved 
in processes such as androgen independence.
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